Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F0MB0
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $41,892
Award facts
- Contract value 100% obligated
- $41,891.63 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $41,891.63 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injections on January 14, 2026, with an ultimate completion date of January 15, 2026. This firm fixed-price, non-set-aside contract represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.99 million through December 2031. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used primarily for treating moderate-to-severe atopic dermatitis, eosinophilic conditions, and asthma, reflecting the federal government's pharmaceutical supply requirements for military healthcare systems.
AmerisourceBergen Drug Corp, as the subsidiary of parent company Cencora, Inc., serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting the Defense Health Agency and military treatment facilities worldwide. The company's portfolio encompasses a broad range of pharmaceutical products including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order exemplifies the routine pharmaceutical supply operations conducted through the comprehensive DLA Troop Support Medical contract vehicle, which enables efficient fulfillment of medical supply needs across the Department of Defense healthcare enterprise.
Quick answers
Who was awarded contract SPE2DR26F0MB0?
SPE2DR26F0MB0 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 14, 2026.
How much is contract SPE2DR26F0MB0 worth?
The government has obligated $41,892 on SPE2DR26F0MB0.
Is contract SPE2DR26F0MB0 an order under another contract?
Yes. SPE2DR26F0MB0 is a delivery order under SPE2DR25D3007, an indefinite delivery contract.
Was contract SPE2DR26F0MB0 competed?
The extent of competition for SPE2DR26F0MB0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award